HALO-Trak
Research type
Research Study
Full title
Proof-of-concept (POC) prospective observational study to test a framework for integration of data streams including molecular genomic markers and wearable device data in patients receiving chemotherapy for advanced cancer.
IRAS ID
312296
Contact name
John D Kelly
Contact email
Sponsor organisation
UCL
Clinicaltrials.gov Identifier
Z6364106/2022/09/12 , UCL Data Protection
Duration of Study in the UK
2 years, 5 months, 1 days
Research summary
Our overarching aim is to determine the relationship between measures of physical performance status including heart rate and steps, health related quality of life (HRQoL) and genomic and immunogenomic phenotype on cancer outcomes in patients receiving chemotherapy or immunotherapy for haematological or metastatic cancer including renal (papillary, and RCC), breast, prostate, and other solid tumours. The primary objective is to test the feasibility of integrating diverse data streams (genomic, HR QoL and biometric) on a novel platform, (Figure 1 & Table 1), capable of integrating datastreams thus generating complex datasets for analyses using machine learning methodologies. Secondary objectives will be to conduct exploratory analysis assessing the relationship between individual and combined data types and cancer outcomes. Analysis using existing and novel computational models will be applied to the data to events in the acute and chronic setting that are common in patients diagnosed with cancer undergoing systemic therapy such as chemotherapy and immunotherapy. The outputs from this study will help inform future studies and trials designed to inform patients about their health status during cancer therapy.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
22/SW/0161
Date of REC Opinion
12 Dec 2022
REC opinion
Further Information Favourable Opinion